Medidata and Cognizant Form Strategic Alliance to Make Digital Transformation Accessible for the Life Sciences

  • Turnkey solutions will accelerate and optimize operational aspects
    of a clinical trial by bringing together industry-leading life science
    software with world-class managed services
  • Life science organizations of all sizes and therapeutic areas can
    leverage enterprise-grade technology and expertise to drive their
    digital transformation

NEW YORK–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/MDSO?src=hash” target=”_blank”gt;#MDSOlt;/agt;–Medidata
(NASDAQ:MDSO) and Cognizant (NASDAQ:CTSH) have entered into a strategic
alliance to offer life science clients comprehensive solutions that
leverage the market’s leading cloud
platform
with world-class business and technology services. This
provides pharmaceutical, biotech, medical device companies, contract
research organizations (CROs), sites and investigators with digital
capabilities to facilitate a fast start to clinical trials, simplify
operational complexities and drive digital transformation.

As part of the multi-year agreement, Cognizant will develop and deliver
a comprehensive set of managed services and solutions specific to
Medidata’s platform. Cognizant’s expertise in business process,
technology and digital services (including biostats, automation and help
desks) will combine with solutions across the Medidata platform, such as
Randomization and Trial Supply Management. This will create clinical
capabilities as-a-service to help address the increasing complexities
and global scale of clinical trials.

As an example of how Medidata is providing more choices for customers,
Medidata Site Payments will seamlessly connect with Cognizant’s Shared
Investigator Platform (SIP) — the industry standard platform designed
to improve the experience of investigators, sites and sponsors.

Clinical trials are becoming more complex to implement and conduct due
to big data, AI and the desire for more targeted therapies. The
professional services component of this alliance provides life science
companies with technology and expertise to architect, implement and
optimize studies.

“Most life science companies have stitched together multiple legacy
solutions and are in dire need for a clinical refresh. This partnership
allows us to offer and manage the most comprehensive platform and suite
of services for our clients so that they can focus on the science rather
than operational complexities,” said Bhaskar Sambasivan, senior vice
president and global head of life sciences at Cognizant.

“This alliance exemplifies the power of Medidata’s technology combined
with the expertise of the broadest and most advanced partner ecosystem,
which we have built in life sciences,” said Tarek Sherif, chairman and
chief executive officer, Medidata. “We are deepening our partnership
with Cognizant to help customers around the globe fully realize the
value of digital transformation.”

About Cognizant

Cognizant (Nasdaq-100: CTSH) is one of the world’s leading professional
services companies, transforming clients’ business, operating and
technology models for the digital era. Our unique industry-based,
consultative approach helps clients envision, build and run more
innovative and efficient businesses. Headquartered in the U.S.,
Cognizant is ranked 195 on the Fortune 500 and is consistently listed
among the most admired companies in the world. Learn how Cognizant helps
clients lead with digital at www.cognizant.com or
follow us @Cognizant.

About Medidata

Medidata is leading the digital transformation of life sciences, with
the world’s most used platform for clinical development, commercial, and
real-world data. Powered by artificial intelligence and delivered by the
#1 ranked industry experts, the Intelligent Platform for Life Sciences
helps pharmaceutical, biotech, medical device companies, and academic
researchers accelerate value, minimize risk and optimize outcomes.
Medidata serves more than 1,000 customers and partners worldwide and
empowers more than 100,000 certified users every day to create hope for
millions of patients. Discover the future of life sciences: www.medidata.com

Contacts

Medidata Solutions
Investors:
Betsy Frank, +1
917-522-4620
bfrank@medidata.com
or
Media:
Erik
Snider, +1 646-362-2997
esnider@medidata.com

Cognizant
For further information, contact:
U.S.: Rick
Lacroix, +1-201-470-8961
richard.lacroix@cognizant.com
or
Josh
Blumenthal, +1-267-244-2841
Joshua.blumenthal@cognizant.com